Research of Exenatide for Overweight/Obese PCOS Patients With IGR

NCT03352869 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication exenatide can help improve blood sugar levels in women who have polycystic ovary syndrome (PCOS), are overweight or obese, and have prediabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 183 people

Who can join Ages 18–45 · female only

Timeline Started 2017-11 · est. completion 2018-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03352869 ↗

Description as written by the study sponsor.

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Treatments tested

Exenatide also known as Byetta Drug

Use Exenatide for 3 months to treat PCOS
Metformin also known as Glucophage Drug

Use Metformin for 3 months to treat PCOS

Main thing measured	Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation
Sponsor	RenJi Hospital
Conditions studied	Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03352869 ↗